Examining racial differences in diffuse large B-cell lymphoma presentation and survival

References

• Shenoy PJ, Malik N, Nooka A, . Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 2011;117:2530–2540.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, . Cancer statistics,2010. CA Cancer J Clin2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010;60:393–408.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Miller TP, O’Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004:221–236.
   Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002–1006.
   PubMed Web of Science ®Google Scholar
• McKelvey EM, Gottlieb JA, Wilson HE, . Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976;38:1484–1493.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24: 3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Ghafoor A, Jemal A, Cokkinides V, . Cancer statistics for African Americans. CA Cancer J Clin 2002;52:326–341.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, . Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Wang M, Burau KD, Fang S, . Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer 2008;113:3231–3241.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Fedewa S, Chen A, . Disparities in the early adoption of chemo-immunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev 2012; Jul 6. [Epub ahead of print].
   Google Scholar
• Foran JM, McClure LA, Clarke CA, . Impact of socioeconomic status and race/ethnicity on survival in diffuse large B-cell lymphoma (DLBCL): a population-based study. Blood 2009;114(Suppl. 1): Abstract 1954.
   Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma.The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Clarke CA, Undurraga DM, Harasty PJ, . Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev 2006;15:630–638.
   PubMed Web of Science ®Google Scholar
• Graiser M, Moore SG, Victor R, . Development of query strategies to identify a histologic lymphoma subtype in a large linked database system. Cancer Inform 2007;3:149–158.
   PubMedGoogle Scholar
• Huang T, Shenoy PJ, Sinha R, . Development of the Lymphoma Enterprise Architecture Database: a caBIG Silver level compliant system. Cancer Inform 2009;8:45–64.
   PubMedGoogle Scholar
• Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523–531.
   Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma.The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Harrington DP, Klatt MM, . Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986;104:757–765.
   PubMed Web of Science ®Google Scholar
• Itoh K, Ohtsu T, Wakita H, . Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma. Ann Oncol 2000;11:1241–1247.
   PubMed Web of Science ®Google Scholar
• Rituximab - Product Approval Information - Licensing Action [Internet]. Rockville (MD): Food and Drug Administration; 1997 November 26 - [cited 2010 Jul 15]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/1997/ritugen112697L.htm
   Google Scholar
• Coiffier B, Haioun C, Ketterer N, . Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927–1932.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Herbrecht R, . Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large-B-cell lymphoma (DLCL): interim results of a randomized GELA trial. Blood 2000;96(Suppl. 1): Abstract 950.
   Google Scholar
• 2010 Census Redistricting Data (Public Law 94-171) Summary File (Georgia) created using American FactFinder [Internet]. Washington (DC): U.S. Census Bureau; 2011 January - [cited 2011 Jun 9]; Available from: http://factfinder2.census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid=DEC_10_PL_P1&prodType=table
   Google Scholar
• Chastain EC, Fisher KE, Bumpers K, . Racial differences in prognostic biomarkers of diffuse large B-cell lymphoma.Presented at United States & Canadian Academy of Pathology Annual Meeting. March 2012. Vancouver, Canada. Abstract 1377.
   Google Scholar
• Morton LM, Turner JJ, Cerhan JR, . Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110:695–708.
   PubMed Web of Science ®Google Scholar
• Turner JJ, Morton LM, Linet MS, . InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 2010;116:e90–e98.
   PubMed Web of Science ®Google Scholar
• Shenoy PJ, Bumpers K, King N, . Black/white differences in the treatment and outcomes of diffuse large B cell lymphoma: a matched cohort analysis. Blood 2009;114(Suppl. 1): Abstract 1392.
   PubMed Web of Science ®Google Scholar
• The A, Li Y, Reddy V, . A comparative study of diffuse large B-cell lymphoma (DLBCL) between African Americans and Caucasians: single-center experience at the University of Alabama at Birmingham (UAB). Blood 2007;110(Suppl. 1): Abstract 4430.
   Google Scholar
• Wang SS, Slager SL, Brennan P, . Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;109:3479–3488.
   PubMed Web of Science ®Google Scholar
• Wang SS, Cozen W, Cerhan JR, . Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res 2007;67:5042–5054.
   PubMed Web of Science ®Google Scholar
• Morton LM, Purdue MP, Zheng T, . Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev 2009;18:1259–1270.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Byrtek M, Taylor MD, . Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: Report from the National LymphoCare Study. Cancer. 2012 Mar 20. doi: 10.1002/cncr.27513. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Vance KT, Kilgore ML, Yun H, . Race and non-Hodgkin's lymphoma: adverse impact of race and treatment delays on survival. A SEER-Medicare population study (1995-2003).Blood 2007; 110(Suppl. 1): Abstract 3578.
   Google Scholar
• Feugier P, Van Hoof A, Sebban C, . Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, . Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C, . Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279–4284.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, . Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754–758.
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Choi WW, . Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26: 4587–4594.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Alacacioglu I, Ozcan MA, Ozkal S, . Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma. Hematology 2009;14:84–89.
   PubMed Web of Science ®Google Scholar
• Choi WW, Weisenburger DD, Greiner TC, . A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494–5502.
   PubMed Web of Science ®Google Scholar
• Peh SC, Gan GG, Lee LK, . Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression in diffuse large B-cell lymphomas in Malaysia. Pathol Int 2008;58:572–579.
   PubMed Web of Science ®Google Scholar
• Shiozawa E, Yamochi-Onizuka T, Takimoto M, . The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res 2007;31:1579–1583.
   PubMed Web of Science ®Google Scholar
• Xia ZG, Xu ZZ, Zhao WL, . The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. Ann Hematol 2010;89:171–177.
   PubMed Web of Science ®Google Scholar
• Kim DH, Du Jung H, Kim JG, . FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720–2725.
   PubMed Web of Science ®Google Scholar
• Mitrovic Z, Aurer I, Radman I, . FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica 2007;92:998–999.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Cheng C, Devidas M, . Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 2011;43:237–241.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Armitage JO. A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk 2010;10:414–423.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Glover R, Lonial S, . Racial Differences In The Incidence and outcomes for patients with hematological malignancies. Curr Prob Cancer 2007;31:182–201.
   PubMedGoogle Scholar